

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# 东曜药业

## TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1875)**

### ELECTION OF MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS

The Company is making arrangements in accordance with Rules 2.07A and 2.07B of the Listing Rules, the Articles of Association and the Companies Ordinance, to offer Shareholders the options to elect for the means of receipt of the Company's future Corporate Communications.

If the Company does not receive a duly completed and signed Reply Form or a response indicating the objection from a Shareholder in writing on or before 31 January 2024, such Shareholder will be deemed to have consented to receive the Website Version of the Company's future Corporate Communications instead of printed copies.

#### INTRODUCTION

The Company announces that pursuant to Rules 2.07A and 2.07B of the Listing Rules, the Articles of Association and the Companies Ordinance, arrangements have been made to offer Shareholders the options to elect for the means of receipt (in printed form or by Website Version) of the Company's future Corporate Communications.

In support of environmental protection, the Company recommends its Shareholders to elect for the Website Version for receiving the Company's future Corporate Communications.

#### ARRANGEMENTS

In accordance with Rules 2.07A and 2.07B of the Listing Rules, the Articles of Association and the Companies Ordinance, the following arrangements have been made by the Company:

1. The Company will send the First Letter dated 29 December 2023 together with the Reply Form, in both English and Chinese, to Shareholders to enable them to elect any of the following options:
  - (i) to access the Website Version of all future Corporate Communications, instead of receiving printed copies by mail; or
  - (ii) to receive by mail the printed version of all future Corporate Communications.

The Reply Form should be completed, signed and returned by post using the mailing label at the bottom of the Reply Form or by hand delivery to the Share Registrar at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong on or before 31 January 2024.

**The First Letter explains that if the Company does not receive the Reply Form or receive a response indicating any objection from the Shareholder on or before 31 January 2024 and until the Shareholder informs the Share Registrar by reasonable prior notice in writing or by sending an email to 1875-ecom@hk.tricorglobal.com, such Shareholder will be deemed to have consented to receive the Website Version, and a notification letter of the publication of the Website Version of the Corporate Communications on the Company’s website will be sent to such Shareholder in the future.**

2. For Shareholders who wish to receive the Corporate Communications in printed form, the Company will send the Corporate Communications to those Shareholders who have made a selection unless and until they inform the Share Registrar at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by reasonable prior notice in writing or by sending an email to 1875-ecom@hk.tricorglobal.com that they wish to receive the Website Version of all future Corporate Communications.
3. When each of the printed future Corporate Communications is sent in accordance with the arrangements described above, the Second Letter together with the Request Form, in both English and Chinese, will be attached to or printed at some prominent place in the relevant Corporate Communications. By completing and returning the Request Form to the Share Registrar by post or by sending an email to 1875-ecom@hk.tricorglobal.com, a Shareholder may at anytime provide his/her/its email address and request to receive the Website Version of future Corporate Communications.
4. For Shareholders who elect to receive the Website Version of future Corporate Communications, the Company will request such Shareholders to provide an email address in the Reply Form or the Request Form for the purposes of receiving (i) email notifications for the publication of the relevant Corporate Communications on the Company’s website as and when Corporate Communications are published on the Company’s website and (ii) all future Actionable Corporate Communications in electronic form from the Company. It is the responsibility of the Shareholders to provide email address that is functional. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any “non-delivery” message.

If no valid and functional email address is provided by a Shareholder in the Reply Form or the Request Form or if a Shareholder is otherwise deemed to have consented to receive the Website Version of future Corporate Communications, the Company will send to such Shareholder by post, (i) a notification letter for the publication of Corporate Communications on the Company’s website and (ii) all future Actionable Corporate Communications in printed form, until such time when such Shareholder has provided a valid and functional email address to the Share Registrar for receiving the same.

5. For those Shareholders who choose, or are deemed to have consented, to receive the Website Version, if for any reason, such Shareholders have difficulty in receiving or gaining access to the Company's website or wish to receive a printed version, the Company will, upon request in writing to the Share Registrar or by email to 1875-ecom@hk.tricorglobal.com, promptly send the relevant Corporate Communications to such Shareholders in printed form free of charge.
6. All future Corporate Communications in accessible format will be available on the Company's website at [www.totbiopharm.com.cn](http://www.totbiopharm.com.cn) and the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk).
7. Shareholders shall have the right at any time by reasonable prior notice in writing to the Share Registrar or by sending a prior notice via email to 1875-ecom@hk.tricorglobal.com specifying their name, address and request, to change the means of receipt of the Corporate Communications.
8. Shareholders can call the hotline of the Share Registrar at (852) 2980 1333 during business hours (9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays) in respect of any queries in relation to the Company's arrangements set out above.
9. The First Letter and the Second Letter will mention that printed copies of future Corporate Communications will be available from the Company and the Share Registrar upon request, as well as on the Company's website at [www.totbiopharm.com.cn](http://www.totbiopharm.com.cn) and on the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk), and that the dial-up hotline service has been provided.

## **DEFINITIONS**

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

“Actionable Corporate Communications”	any corporate communication from the Company that seeks instructions from holders of any of the Company's securities on how they wish to exercise their rights or make an election as the securities holders of the Company, including but not limited to, (a) election forms in connection with a dividend payment, (b) excess application forms in connection with a rights issue or open offer, (c) applications forms for assured entitlement under an open offer, (d) acceptance forms in connection with takeovers, mergers and share buy-backs, and (e) provisional allotment letters in connection with a rights issue
“Articles of Association”	the amended and restated articles of association of the Company which were adopted on 30 September 2019 and became effective on 28 October 2019

“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Company”	TOT BIOPHARM International Company Limited (東曜藥業股份有限公司) (formerly known as TOT BIOPHARM International Company Limited (東源國際醫藥股份有限公司)), a company incorporated in Hong Kong with limited liability on 4 December 2009 whose Shares are listed on the Stock Exchange (stock code: 1875)
“Corporate Communications”	any document issued or to be issued by the Company for the information or action of holders of any of the Company’s securities, including but not limited to: (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form
“First Letter”	a letter dated 29 December 2023 to be sent by the Company to the Shareholders together with the Reply Form
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
“Reply Form”	a reply form (with a freepost mailing label for posting in Hong Kong) to be sent together with the First Letter
“Request Form”	a request form (with a freepost mailing label for posting in Hong Kong) to be sent together with the Second Letter
“Second Letter”	a letter to be sent to the Shareholders by the Company together with the Request Form when the Company disseminates future Corporate Communications
“Share(s)”	ordinary share(s) of the Company
“Share Registrar”	Tricor Investor Services Limited, the share registrar of the Company in Hong Kong, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong
“Shareholder(s)”	holder(s) of the Share(s)

“Stock Exchange”

The Stock Exchange of Hong Kong Limited

“Website Version”

the version of Corporate Communications in electronic form published, in both English and Chinese, on the Company’s website

By order of the Board  
**TOT BIOPHARM International Company Limited**  
**Dr. Liu, Jun**  
*Chief Executive Officer and Executive Director*

Hong Kong, 28 December 2023

*As at the date of this announcement, the executive director of the Company is Dr. Liu, Jun; the non-executive directors of the Company are Mr. Fu, Shan, Ms. Yeh-Huang, Chun-Ying and Dr. Liu, Weidong; and the independent non-executive directors of the Company are Ms. Hu, Lan, Mr. Chang, Hong-Jen and Dr. Wang, De Qian.*